Clinical Trials Logo

Small Bowel Cancer clinical trials

View clinical trials related to Small Bowel Cancer.

Filter by:

NCT ID: NCT06101277 Recruiting - Colorectal Cancer Clinical Trials

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

LIVELONG
Start date: October 5, 2023
Phase: N/A
Study type: Interventional

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

NCT ID: NCT05780684 Recruiting - Colorectal Cancer Clinical Trials

Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer

Start date: July 14, 2023
Phase: N/A
Study type: Interventional

This is a single-arm clinical trial that will evaluate the feasibility of a chemotherapy regimen adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose. Study participants will also receive oxaliplatin chemotherapy together with 5-FU, at standard doses. The goal of the study is to examine the feasibility and effectiveness of this approach, using individualized dose escalation of 5-FU in patients who do not have serious side effects at lower doses.

NCT ID: NCT05670574 Recruiting - Quality of Life Clinical Trials

Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors

Start date: November 4, 2016
Phase: N/A
Study type: Interventional

The study is designed to investigate the safety and efficacy of central D3 lymphadenectomy in cases of small bowel tumors. Such dissection is under debate; consensus guidelines are vague when it comes to surgical techniques and practice is highly variable.

NCT ID: NCT05565417 Recruiting - Colorectal Cancer Clinical Trials

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Start date: November 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: - Find the recommended dose of IMT-009 that can be safely given to participants - Learn more about the side effects of IMT-009 - Learn more about pharmacokinetics of IMT-009 - Learn more about the effectiveness of IMT-009 - Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009

NCT ID: NCT05277766 Recruiting - Colorectal Cancer Clinical Trials

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

PIPAC-NAL-IRI
Start date: November 21, 2022
Phase: Phase 1
Study type: Interventional

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.

NCT ID: NCT04566393 Available - Colorectal Cancer Clinical Trials

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

NCT ID: NCT04526886 Completed - Colorectal Cancer Clinical Trials

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for reducing unplanned delays in patients receiving FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)-type chemotherapy, while maintaining acceptable chemotherapy dose-intensity.

NCT ID: NCT04498767 Recruiting - Pancreatic Cancer Clinical Trials

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

OligoRARE
Start date: June 10, 2021
Phase: N/A
Study type: Interventional

This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers. Patients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease. The primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.

NCT ID: NCT04316078 Completed - Gastric Cancer Clinical Trials

A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies

Start date: March 15, 2020
Phase: N/A
Study type: Interventional

A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.

NCT ID: NCT04028479 Recruiting - Breast Cancer Clinical Trials

The Registry of Oncology Outcomes Associated With Testing and Treatment

ROOT
Start date: May 5, 2021
Phase:
Study type: Observational [Patient Registry]

This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.